Further validation of the Multidimensional Fatigue Inventory in a US adult population sample

Jin-Mann S Lin, Dana J Brimmer, Elizabeth M Maloney, Ernestina Nyarko, Rhonda Belue, William C Reeves, Jin-Mann S Lin, Dana J Brimmer, Elizabeth M Maloney, Ernestina Nyarko, Rhonda Belue, William C Reeves

Abstract

Background: The Multidimensional Fatigue Inventory (MFI-20) was developed in 1995. Since then, it has been widely used in cancer research and cancer-related illnesses but has never been validated in fatiguing illnesses or in a large US population-selected sample. In this study, we sought to examine the reliability and validity of the MFI-20 in the population of the state of Georgia, USA. Further, we assessed whether the MFI-20 could serve as a complementary diagnostic tool in chronically fatigued and unwell populations.

Methods: The data derive from a cross-sectional population-based study investigating the prevalence of chronic fatigue syndrome (CFS) in Georgia. The study sample was comprised of three diagnostic groups: CFS-like (292), chronically unwell (269), and well (222). Participants completed the MFI-20 along with several other measures of psychosocial functioning, including the Medical Outcomes Survey Short Form-36 (SF-36), the Zung Self-Rating Depression Scale (SDS), and the Spielberger State-Trait Anxiety Inventory (STAI). We assessed the five MFI-20 subscales using several criteria: inter-item correlations, corrected item-total correlations, internal consistency reliability (Cronbach's alpha coefficients), construct validity, discriminant (known-group) validity, floor/ceiling effects, and convergent validity through correlations with the SF-36, SDS, and STAI instruments.

Results: Averaged inter-item correlations ranged from 0.38 to 0.61, indicating no item redundancy. Corrected item-total correlations for all MFI-20 subscales were greater than 0.30, and Cronbach's alpha coefficients achieved an acceptable level of 0.70. No significant floor/ceiling effect was observed. Factor analysis demonstrated factorial complexity. The MFI-20 also distinguished clearly between three diagnostic groups on all subscales. Furthermore, correlations with depression (SDS), anxiety (STAI), and functional impairment (SF-36) demonstrated strong convergent validity.

Conclusions: This study provides support for the MFI-20 as a valuable tool when used in chronically unwell and well populations. It also suggests that the MFI-20 could serve as a complementary diagnostic tool in fatiguing illnesses, such as CFS.

References

    1. Lewis G, Wessely S. The epidemiology of fatigue: more questions than answers. J Epidemiol Community Health. 1992;46(2):92–97. doi: 10.1136/jech.46.2.92.
    1. Smets EM, Garssen B, Bonke B. Manual; Multidimensional Fatigue Inventory. Amsterdam: Medical Psychology, Academic Medical Centre; 1995.
    1. Ericsson A, Mannerkorpi K. Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20. Disabil Rehabil. 2007;29(22):1665–1670.
    1. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord. 2008;23(10):1428–34. doi: 10.1002/mds.21667.
    1. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, Weinstock-Guttman B. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 2005;231(1-2):29–34. doi: 10.1016/j.jns.2004.12.009. Epub 2005 Jan 26.
    1. Smets EM, Garssen B, Cull A, De Haes JC. Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. Br J Cancer. 1996;73(2):241–245.
    1. Kennedy SH. Core symptoms of major depressive disorder relevance to diagnosis and treatment. Dialogues in ClinicalNeuroscience. 2008;10:271–7.
    1. Bakshi R, Shaikh ZA, Miletich RS, Czamecki D, Dmochowski J, Henschel K, Janardhan V, Dubey N, Kinkel PR. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Multiple Sclerosis. 2000;6:181–185.
    1. Kroencke DC, Lynch SG, Denny DR. Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern. Multiple Sclerosis. 2000;6:131–136.
    1. Pittion-Vouyovitch S, Debouverie M, Guillemin F, Vandenberghe N, Anxionnat R, Vespignani H. Fatigue in multiple sclerosis is related to disability, depression and quality of life. Journal of Neurological Sciences. 2006;243:39–45. doi: 10.1016/j.jns.2005.11.025.
    1. Addington AM, Gallo JJ, Ford DE, Eaton WW. Epidemiology of unexplained fatigue and major depression in the community: The Baltimore ECA Follow-up, 1981-1994. Psychological Medicine. 2001;31:1037–1044. doi: 10.1017/S0033291701004214.
    1. Fuller-Thomson E, Nimigon J. Factors associated with depression among individuals with chronic fatigue syndrome: findings from a nationally representative survey. Fam Pract. 2008;25(6):414–22. doi: 10.1093/fampra/cmn064. Epub 2008 Oct 3.
    1. Nater U M, Lin J-M S, Maloney E M, Jones J F, Tian H, Boneva R S, Raison C L, Reeves W C, Heim C. Psychiatric Comorbidity in Persons With Chronic Fatigue Syndrome Identified From the Georgia Population. Psychosom Med. 2009;71(5):557–65. doi: 10.1097/PSY.0b013e31819ea179. Epub 2009 May 4.
    1. Roy-Byrne P, Afari N, Ashton S, Fishcer M, Goldberg J, Buckwald D. Chronic fatigue and anxiety/depression: a twin-study. British Journal of Psychiatry. 2002;180:29–34. doi: 10.1192/bjp.180.1.29.
    1. Smets EM, Garssen B, Bonke B, De Haes JC. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. Journal of Psychosomatic Research. 1995;39:315–325. doi: 10.1016/0022-3999(94)00125-O.
    1. Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer. 1998;6(2):101–108. doi: 10.1007/s005200050142.
    1. Hagelin CL, Wengström Y, Runesdotter S, Fürst CJ. The psychometric properties of the Swedish Multidimensional Fatigue Inventory MFI-20 in four different populations. Acta Oncol. 2007;46(1):97–104. doi: 10.1080/02841860601009430.
    1. Gentile S, Delarozière JC, Favre F, Sambuc R, San Marco JL. Validation of the French 'multidimensional fatigue inventory' (MFI 20) Eur J Cancer Care (Engl) 2003;12(1):58–64. doi: 10.1046/j.1365-2354.2003.00295.x.
    1. Dekkers OM, Biermasz NR, Smit JW, Groot LE, Roelfsema F, Romijn JA, Pereira AM. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol. 2006;154(3):483–489. doi: 10.1530/eje.1.02114.
    1. Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Brit J Haem. 2003;121:270–274. doi: 10.1046/j.1365-2141.2003.04272.x.
    1. Schwarz R, Krauss O, Hinz A. Fatigue in the general population. Onkologie. 2003;26:140–144. doi: 10.1159/000069834.
    1. Schneider RA. Reliability and validity of the Multidimensional Fatigue Inventory (MFI-20) and the Rhoten Fatigue Scale among rural cancer outpatients. Cancer Nursing. 1998;21(5):370–373. doi: 10.1097/00002820-199810000-00009.
    1. Schneider RA. Preliminary data on the Multidimensional Fatigue Inventory-20 from female caregivers of male hemodialysis patients. Psychol Rep. 2001;88(3 Pt 1):699–700. doi: 10.2466/PR0.88.3.699-700.
    1. Reeves WC, Jones JJ, Maloney EM, Heim C, Hoaglin DC, Boneva RS, Morrissey M, Devlin R. Prevalence of chronic fatigue syndrome in metropolitan, urban, and rural Georgia. Population Health Metrics. 2007;8(5):5. doi: 10.1186/1478-7954-5-5.
    1. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Medical Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. Ware JE. SF-36 health survey update. Spine. 2000;25:3130–3139. doi: 10.1097/00007632-200012150-00008.
    1. Zung W WK. A rating instrument for anxiety disorders. Psychosomatics. 1971.
    1. Spielberger CD. Manual for the State-Trait Anxiety Inventory (STAI) Palo Alto, CA: Consulting PsychologistsPress; 1983.
    1. Jastak S, Wilkinson G. Wide Range Achievement Test-Revisited. Wilmington, Delaware: Jastak Associates Inc; 1984.
    1. Nunnally JC, Bernstein IH. Psychometric theory. 3. New York: McGraw-Hill; 1994.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334. doi: 10.1007/BF02310555.
    1. Terwee CB, Bot SD, de Boer MR, Windt DA van der, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J ClinEpidemiol. 2007;60(1):34–42. Epub 2006 Aug 24.
    1. Nunnally JC. Psychometric testing. 2. New York: McGraw-Hill; 1978.
    1. Zeller RA, Carmines EG. Measurement in the social sciences: the link between theory and data. London: Cambridge University Press; 1979.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2. New Jersey: Erlbaum; 1988.
    1. Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage. 2004;27(1):14–23. doi: 10.1016/j.jpainsymman.2003.06.003.
    1. Purcell A, Fleming J, Bennett S, Burmeister B, Haines T. Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population. Support Care Cancer. 2009. in press .
    1. de Jong N, Candel MJ, Schouten HC, Abu-Saad HH, Courtens AM. Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol. 2005;16(3):372–82. doi: 10.1093/annonc/mdi095. Epub 2005 Jan 27.
    1. Watt T, Groenvold M, Bjorner JB, Noerholm V, Rasmussen NA, Bech P. Fatigue in the Danish general population. Influence of sociodemographic factors and disease. J Epidemiol Community Health. 2000;54(11):827–833. doi: 10.1136/jech.54.11.827.
    1. Breslin E, Schans C Van der, Breukink S, Meek P, Mercer K, Volz W, Louie S. Perception of fatigue and quality of life in patients with COPD. Chest. 1998;114:958–964. doi: 10.1378/chest.114.4.958.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi